Effect of N-Acetylcysteine on Positive and Negative Syndrome Scale associated with Schizophrenia: A Meta-Analysis

A. Ghaderi, A. Bussu, C. Tsang, S. Jafarnejad
{"title":"Effect of N-Acetylcysteine on Positive and Negative Syndrome Scale associated with Schizophrenia: A Meta-Analysis","authors":"A. Ghaderi, A. Bussu, C. Tsang, S. Jafarnejad","doi":"10.22038/RCM.2020.50482.1329","DOIUrl":null,"url":null,"abstract":"Background and objective: N-acetylcysteine (NAC), a precursor of L-cysteine with antioxidant, anti-inflammatory and neurotropic effects, is a promising agent in alleviating symptoms associated with schizophrenia.  However, the role of NAC on parameters of Positive and Negative Syndrome Scale (PANSS) remain uncertain. This systematic review and meta-analysis explored the effect of NAC on parameters of PANSS in patients with chronic schizophrenia. \nMethods: We searchedPubmed/MEDLINE™, PsycNET™, PsycLIT™, Scopus™ and Google Scholar™  for studies on the effect of NAC on PANSS in patients with schizophrenia from inception to March 2019. We adopted medical and non-medical subjects headings (MeSH, non-MeSH) and several keywords, including  “NAC”, “N-acetylcysteine”, “N-acetyl cysteine”, “Acetylcysteine”, “N-Acetyl-L-cysteine”,  “schizophrenia”, “psychotic disorder”, “psychosis”, “schizoaffective” and “dementia praecox”. \nResults: We identified seven trials with274 patients meeting the inclusion criteria, with follow up between 8-52 weeks, and NAC supplementation between 1200-3600 mg/day. Significant improvements in PANSS were identified following NAC for total (SMD=-0.61, 95% CI = -0.91, -0.31 ; P<0.001), general (SMD = -0.58; 95% CI = -0.90, -0.26; P=0.0004); and negative (SMD = -0.56; 95% CI = -0.92, -0.21; P = 0.001) scores, respectively. No significant heterogeneity was found among studies. Significant reductions were observed following sub-group analysis in trials ≤ 24 weeks duration, with appreciable effect size for total (SMD= -0.83), general (SMD= -0.67) and negative (SMD=-1.09) scores. \nConclusion: Supplementation of NAC was effective in alleviating PANSS symptoms associated with schizophrenia in trials ≤ 24 weeks duration. The use of NAC as an adjunct seems promising and further investigation is warranted to determine its precise role.","PeriodicalId":21081,"journal":{"name":"Reviews in Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/RCM.2020.50482.1329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: N-acetylcysteine (NAC), a precursor of L-cysteine with antioxidant, anti-inflammatory and neurotropic effects, is a promising agent in alleviating symptoms associated with schizophrenia.  However, the role of NAC on parameters of Positive and Negative Syndrome Scale (PANSS) remain uncertain. This systematic review and meta-analysis explored the effect of NAC on parameters of PANSS in patients with chronic schizophrenia. Methods: We searchedPubmed/MEDLINE™, PsycNET™, PsycLIT™, Scopus™ and Google Scholar™  for studies on the effect of NAC on PANSS in patients with schizophrenia from inception to March 2019. We adopted medical and non-medical subjects headings (MeSH, non-MeSH) and several keywords, including  “NAC”, “N-acetylcysteine”, “N-acetyl cysteine”, “Acetylcysteine”, “N-Acetyl-L-cysteine”,  “schizophrenia”, “psychotic disorder”, “psychosis”, “schizoaffective” and “dementia praecox”. Results: We identified seven trials with274 patients meeting the inclusion criteria, with follow up between 8-52 weeks, and NAC supplementation between 1200-3600 mg/day. Significant improvements in PANSS were identified following NAC for total (SMD=-0.61, 95% CI = -0.91, -0.31 ; P<0.001), general (SMD = -0.58; 95% CI = -0.90, -0.26; P=0.0004); and negative (SMD = -0.56; 95% CI = -0.92, -0.21; P = 0.001) scores, respectively. No significant heterogeneity was found among studies. Significant reductions were observed following sub-group analysis in trials ≤ 24 weeks duration, with appreciable effect size for total (SMD= -0.83), general (SMD= -0.67) and negative (SMD=-1.09) scores. Conclusion: Supplementation of NAC was effective in alleviating PANSS symptoms associated with schizophrenia in trials ≤ 24 weeks duration. The use of NAC as an adjunct seems promising and further investigation is warranted to determine its precise role.
N-乙酰半胱氨酸对精神分裂症阳性和阴性综合征量表的影响:Meta分析
背景与目的:n -乙酰半胱氨酸(NAC)是l -半胱氨酸的前体,具有抗氧化、抗炎和嗜神经作用,是一种有希望缓解精神分裂症相关症状的药物。然而,NAC对正、负证量表(PANSS)参数的影响尚不明确。本系统综述和荟萃分析探讨了NAC对慢性精神分裂症患者PANSS参数的影响。方法:我们检索pubmed /MEDLINE™、PsycNET™、PsycLIT™、Scopus™和谷歌Scholar™,检索从成立到2019年3月NAC对精神分裂症患者PANSS影响的研究。我们采用医学和非医学主题词(MeSH, non-MeSH)和几个关键词,包括“NAC”,“n-乙酰半胱氨酸”,“n-乙酰半胱氨酸”,“乙酰半胱氨酸”,“n-乙酰- l-半胱氨酸”,“精神分裂症”,“精神障碍”,“精神病”,“分裂情理性”和“早发性痴呆”。结果:我们确定了7项试验,274例患者符合纳入标准,随访8-52周,NAC补充量为1200- 3600mg /天。NAC后PANSS有显著改善(SMD=-0.61, 95% CI = -0.91, -0.31;P<0.001),一般(SMD = -0.58;95% ci = -0.90, -0.26;P = 0.0004);负(SMD = -0.56);95% ci = -0.92, -0.21;P = 0.001)评分。各研究间未发现显著异质性。在持续时间≤24周的试验中,亚组分析后观察到显著降低,总评分(SMD= -0.83)、一般评分(SMD= -0.67)和阴性评分(SMD=-1.09)的效应量明显。结论:在≤24周的试验中,补充NAC可有效缓解与精神分裂症相关的PANSS症状。NAC作为一种辅助剂的使用似乎很有希望,需要进一步的研究来确定它的确切作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信